News

WuXi AppTec shares surged after the Chinese biotechnology company said it expected to post sharply higher net profit for the first half. The company's Hong Kong-listed shares climbed over 12% in early ...
Chinese pharmaceutical giant WuXi AppTec (SS:603259) expects its first-half net profit to more than double, driven by soaring ...
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0416 ET – Singapore’s growth outlook remains highly uncertain ...
The Hang Seng Index rose 1.4 per cent to 24,355.75 at 10.03am local time and the Hang Seng Tech Index gained 1.2 per cent. On ...
WuXi AppTec will provide additional details when the Company releases its results for the first half of 2025 on July 29, 2025. For more information, please refer to the Company's related announcements ...
ET Net News Agency, 11 July 2025] Nomura raised the target price for Wuxi AppTec (02359) to HKD102.77 from HKD84.59 and maintained the "buy" rating. The research house said it li ...
WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences ...
WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties. Its Hong Kong-listed shares fell 3.9% in Tuesday afternoon.
ET Net News Agency, 11 July 2025] A direct manual trade of 914,900 shares of WUXI APPTEC (02359) was registered at 9:30a.m. The deal amounted to HK$77.84m, or at HK$85.075 per sh ...
A group of fisheries officials recently visited Wuxi in East China's Jiangsu province to attend the 34th Governing Council ...